Septerna, Inc. Files 8-K Report

Ticker: SEPN · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1984086

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

TL;DR

Septerna filed an 8-K, likely with financial updates. Watch for details.

AI Summary

On September 3, 2025, Septerna, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and includes Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates Septerna, Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific financial or operational risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Septerna, Inc.?

The filing is primarily for Regulation FD Disclosure and includes Financial Statements and Exhibits, as indicated by the Item Information.

When was this 8-K report filed by Septerna, Inc.?

The report was filed on September 3, 2025.

What is Septerna, Inc.'s principal executive office address?

Septerna, Inc.'s principal executive offices are located at 250 East Grand Avenue, Suite 65, South San Francisco, CA 94080.

What is Septerna, Inc.'s telephone number?

Septerna, Inc.'s telephone number is (650) 338-3533.

What is Septerna, Inc.'s Standard Industrial Classification (SIC) code?

Septerna, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2025-09-03 07:00:21

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits 99.1 Corporate Presentation of Septerna, Inc., dated September 2025, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Septerna, Inc. Date: September 3, 2025 By: /s/ Jeffrey Finer, M.D., Ph.D. Jeffrey Finer, M.D., Ph.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing